Chantix
Product Images NDC 21695-633

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Chantix (NDC 21695-633). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (F990eca6 Fe6f 4423 A118 4b7b970995a1 01)

Chemical Structure (F990eca6 Fe6f 4423 A118 4b7b970995a1 01)
Chemical structure diagram showing the molecular structures related to Chantix. The image depicts two chemical structures, including one with a bicyclic framework containing nitrogen atoms and another smaller structure with multiple hydroxyl groups and a carboxyl group.*
FDA Label Image

Figure 1 (F990eca6 Fe6f 4423 A118 4b7b970995a1 02)

Figure 1 (F990eca6 Fe6f 4423 A118 4b7b970995a1 02)
A bar chart comparing percentages across different studies (Study 2 to Study 5) for Chantix (0.5 mg and 1.0 mg doses), bupropion SR 150 mg BID, and placebo groups. Each study displays multiple bars representing different treatments, showing variable response rates with error bars indicating variability.*
FDA Label Image

Figure 2 (F990eca6 Fe6f 4423 A118 4b7b970995a1 03)

Figure 2 (F990eca6 Fe6f 4423 A118 4b7b970995a1 03)
A bar chart comparing the effects of Chantix (0.5 mg, 1.0 mg) and placebo across four different studies. Each study shows percent values on the y-axis with Chantix dosages and placebo groups on the x-axis, highlighting differences between the active treatment and placebo groups with additional error bars for variability.*
FDA Label Image

Figure 3 (F990eca6 Fe6f 4423 A118 4b7b970995a1 04)

Figure 3 (F990eca6 Fe6f 4423 A118 4b7b970995a1 04)
A line graph showing the percentage of continuous abstinent individuals over a period of 52 weeks post-treatment follow-up. Two lines are displayed: one for Chantix 1.0 mg BID and one for placebo, illustrating higher rates of abstinence in the Chantix group compared to placebo throughout the follow-up period.*
FDA Label Image

Company Logo (F990eca6 Fe6f 4423 A118 4b7b970995a1 05)

FDA Label Image

Company Logo (F990eca6 Fe6f 4423 A118 4b7b970995a1 06)

FDA Label Image

Chantix 0.5mg (F990eca6 Fe6f 4423 A118 4b7b970995a1 07)

Chantix 0.5mg (F990eca6 Fe6f 4423 A118 4b7b970995a1 07)
Label for Chantix 0.5 mg tablets, NDC 21695-633-56, distributed by Physician Partner and manufactured by Pfizer Ireland Pharmaceuticals Dublin. The label includes dosage, ingredient equivalence, product ID RC063356, storage instructions, and safety warnings. The tablet is described as film-coated, white to off-white, debossed with markings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.